Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Shiying He
Advertisement
Shiying He is a senior consultant for Simon-Kucher.
Articles by Shiying He
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
Novo Nordisk Stock Reacts to Recent Board Changes
3
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
